
News
Filter Results
Displaying 121–130 of 508
-
Sep 22, 2022
Initiatives to increase engagement and awareness around blinding retinal diseases.
-
Sep 15, 2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene-agnostic therapy products and advance CRISPR-based genome editing portfolio.
-
Sep 13, 2022
Foundation Fighting Blindness Makes Key Appointments to Leadership Team
Several executives promoted to continue the advancement of the Foundation’s notable research and philanthropic efforts.
-
Sep 8, 2022
Iveric Bio’s Zimura for Advanced Dry AMD Meets Endpoint in Second Phase 3 Clinical Trial
The company plans to seek FDA approval for the emerging therapy in first quarter of 2023
-
Aug 25, 2022
Belite Bio Launching Phase 3 Clinical Trial for Stargardt Disease Drug
The company’s drug is designed to reduce accumulation of toxins that cause vision loss.
-
Aug 11, 2022
ProQR Seeking to Partner Ophthalmic Programs
The company is halting its clinical programs for LCA10 and USH2A as it seeks a new partner
-
Aug 10, 2022
Funding for the new grants was made possible by Foundation’s strong donor base and philanthropic partners
-
Jul 29, 2022
Progress toward a stem cell–based therapy for blindness
A multi-institutional effort led by researchers at the School of Veterinary Medicine is taking steps to develop an effective technique to regenerate photoreceptors cells and restore sight in people with vision disorders.
-
Jul 25, 2022
The emerging therapy is designed to restore vision for people with advanced retinal degenerative diseases
-
Jul 22, 2022
Apellis’ Treatment for Advanced Dry AMD to Receive Priority Review from FDA
There are currently no FDA-approved therapies for geographic atrophy (GA), the advanced form of dry AMD.